Clinical trial
Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients…
NCT00145158 · Ludwig Institute for Cancer Research, Other · Terminated
Key facts
| NCT number | NCT00145158 |
|---|---|
| Title | Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma |
| Official title | Phase I/II Study of Immunization With Multiple Peptides Mixed With the Immunological Adjuvant CpG 7909 or Montanide ISA51 in HLA-A2 Patients With Metastatic Cutaneous Melanoma |
| Lead sponsor | Ludwig Institute for Cancer Research, Other |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Melanoma |
| Intervention type | Biological |
| Interventions | 8 HLA-A2-restricted peptides and Montanide ISA51, 8 HLA-A2-restricted peptides and CpG 7909 |
| Enrollment | 23 |
| Start date | Jan 1, 2005 |
| Primary completion | Nov 30, 2007 |
| Completion | Mar 12, 2009 |
| First posted | Sep 5, 2005 |
| Last update posted | Oct 10, 2022 |
| Countries | Belgium |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: